Last updated: April 23, 2026
Which firms supply cimetidine (API) for pharma makers?
Cimetidine is an established generic active pharmaceutical ingredient (API). Suppliers for cimetidine typically fall into two buckets: (1) API manufacturers that sell cimetidine bulk API under cGMP, and (2) contract manufacturers that can supply finished dosage forms (tablets) and/or API intermediates. Sourcing is usually handled through API distributors with validated supplier networks.
The cimetidine market is supplied by a mix of China-based bulk API makers, Indian generic API manufacturers, and European distributors. The most reliable route for procurement is to qualify suppliers via DMF/CEP status, recent inspection outcomes, and CoA traceability rather than rely on catalog availability.
What supplier categories matter for cimetidine procurement?
| Procurement need |
Supplier type |
What you validate in documents |
| Bulk API for formulation |
API manufacturer |
cGMP compliance, DMF (if applicable), CoA/traceability, impurity profile, polymorph/grade (if relevant) |
| Finished tablets for market release |
Finished dosage contract manufacturer |
Market authorization, batch records, stability, dissolution, labeling compliance |
| Supply continuity and lead-time |
API distributor / sourcing house |
Inventory sourcing, chain-of-custody, lot genealogy, rapid CoA turnaround |
| Cost and scale-up |
API manufacturer + tolling arrangements |
Tech transfer scope, scale capability, change control history |
How do buyers typically choose between cimetidine API suppliers?
- Regulatory dossier status: DMF holders and CEP-backed sources are easier to qualify for dossier submissions.
- Quality system maturity: cGMP record, deviation control, and inspection history.
- Lot consistency: impurity limits, residual solvents, water content, and assay stability across batches.
- Operational risk: single-site manufacturing versus multi-site sourcing.
- Contract terms: lead time, min order quantity, and change notification timelines.
Where does cimetidine sourcing concentrate geographically?
Cimetidine is widely produced in bulk API by manufacturers concentrated in Asia. Buyers in regulated markets usually source through qualified distributors and/or pre-approved API manufacturers, then manage regulatory filing via DMFs or equivalent documentation.
What is the cimetidine supply specification baseline buyers expect?
For procurement, suppliers generally align to pharmacopeial expectations (USP/EP/BP) and define internal specs that cover:
- Identity and potency: assay of cimetidine
- Impurities: process-related impurities and degradants (with defined limits)
- Moisture and physical properties: water content and particle-related characteristics (as specified)
- Residual solvents: if applicable, aligned to ICH Q3C
- Microbiology: if required by the supplier’s cGMP spec for the API grade
- Sterility is not applicable for API unless the supplier offers a special grade
Which supplier channels provide cimetidine finished forms?
Where tablets are sourced, procurement commonly uses:
- Generic finished-dose manufacturers with established dossiers
- Contract manufacturing organizations with tablet lines and validated dissolution profiles
- Distributors that bundle API sourcing and dosage manufacturing under one quality umbrella
Buyers typically require stability data and a documented bridge to the approved formulation, especially when switching from one global manufacturer to another.
What supplier due diligence is standard for an established API like cimetidine?
| Due diligence checkpoint |
Why it matters |
| CoA review for each lot |
Confirms assay and impurity compliance at release |
| Impurity trend review across lots |
Identifies process drift |
| Batch record access under NDA |
Confirms consistency with approved controls |
| Change control documentation |
Prevents unapproved spec/process moves |
| Inspection outcome screening |
Reduces compliance risk |
| Shipping and storage conditions |
Minimizes degradation and spec excursions |
Actionable short list: where to start supplier qualification (process, not names)
Because the cimetidine supplier list changes frequently with distribution agreements, approvals, and catalog status, the fastest actionable path is qualification by dossier and quality documentation:
- DMF holders (API manufacturers) for cimetidine
- CEP-backed manufacturers (where applicable in target jurisdictions)
- Qualified API distributors with documented lot traceability and rapid CoA turnaround
- Finished-dose CMO partners if tablets are required, with demonstrated dissolution and stability alignment
Key Takeaways
- Cimetidine sourcing is dominated by established generic API supply networks, with procurement usually handled through DMF/CEP-aligned manufacturers and qualified distributors.
- The buyer’s strongest selection criteria are dossier status, cGMP track record, impurity and CoA consistency, and change control discipline, not catalog availability.
- For finished tablets, qualification hinges on formulation comparability, stability, and dissolution alignment, plus documented manufacturing process controls.
- Practical sourcing starts with pre-qualification of DMF/CEP-linked manufacturers and distributor-controlled lot traceability.
FAQs
-
Is cimetidine commonly sourced as API or finished tablets?
Most pharma formulation supply chains source cimetidine as bulk API; finished tablets are typically sourced from dosage CMOs or finished-dose manufacturers when the buyer does not formulate.
-
What documents matter most when switching cimetidine suppliers?
CoA history (assay and impurities), impurity trend data, batch genealogy, and change control records tied to the supplier’s dossier.
-
What quality risks are most relevant for an established API like cimetidine?
Impurity drift across production lots, residual solvent and water specification excursions, and undocumented process changes.
-
Do cimetidine suppliers differ significantly in regulatory dossier readiness?
Yes. DMF/CEP-backed sources usually reduce qualification friction versus suppliers without active dossier support.
-
How should buyers reduce lead-time and supply continuity risk?
Qualify at least two sources (manufacturer and/or distributor channel), use safety stock on critical lots, and ensure contractual change notification timelines.
References
[1] U.S. Food and Drug Administration (FDA). Drug Master Files (DMFs). https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs
[2] European Directorate for the Quality of Medicines & HealthCare (EDQM). Certificates of Suitability (CEPs). https://www.edqm.eu/en/medicines/ceps
[3] International Council for Harmonisation (ICH). ICH Q3C: Impurities: Residual Solvents. https://www.ich.org/page/quality-guidelines
[4] International Council for Harmonisation (ICH). ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products. https://www.ich.org/page/quality-guidelines
